A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Conditions

Myeloid and Monocytic Leukemia

What is the purpose of this trial?

This randomized phase III trial studies ;cytarabine ;and ;daunorubicin ;hydrochloride or idarubicin and ;cytarabine ;with or without vorinostat to see how well they work in treating younger patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as ;cytarabine, ;daunorubicin ;hydrochloride, idarubicin, and vorinostat, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. It is not yet known which combination chemotherapy is more effective in treating acute myeloid leukemia.


Participation Guidelines

Age:
15 Years - 60 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Southwest Oncology Group (SWOG)
Dates:
08/20/2013
Last Updated:
Study HIC#:
1305012088